Testing dasatinib and quercetin in diabetes-related kidney disease
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether two medicines (dasatinib and quercetin) can affect “cell aging” in people with chronic kidney disease related to diabetes. You may be asked to take pills for a short period and complete follow-up visits to measure how your body responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 40 and 80 years old
- You have chronic kidney disease, with an eGFR between 15 and 45
- You have diabetes and take diabetes medicines
- Your diabetes control is not very high (A1c below 10%)
- You’re able to take pills by mouth and give informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called AZD4248 to see if it's safe for healthy people and for people with chronic kidney disease and type 2 diabetes. It also checks if a home device can accurately measure kidney function.
This trial tests if a medicine called finerenone can protect kidney function in people with type 2 diabetes and early-to-moderate chronic kidney disease. It may be an option if you are already on blood pressure medication and have some protein in your urine.
This study tests a personalized medication approach to lower kidney and heart risks in people with type 2 diabetes and early-to-moderate kidney disease. It may help you if you have a high chance of heart problems and can start new medications.
This study tests if matching treatments to your specific kidney disease markers can better protect your kidneys. It looks at how well Finerenone, Dapagliflozin, and Semaglutide work alone or in a sequence.
This trial tests whether senolytic drugs (which remove aging cells) can help slow or stop worsening of secondary progressive multiple sclerosis. It may be an option if you are no longer taking MS disease-modifying therapies.
This study tests whether a common diabetes medication (SGLT2 inhibitor) can help people with autosomal dominant polycystic kidney disease (ADPKD) maintain kidney function longer. If you have fast-growing kidney cysts and are between 18 and 60 years old, this trial may be an option.
Hear when a new Chronic kidney disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.